查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1620215

冠状动脉支架市场：依类型、依材料类型、依最终用户、按地区，2024-2031

Coronary Stent Market By Type (Bare-Metal Stents (BMS), Drug-Eluting Stents (DES)), By Material Type (Polymer-Based Stents, Metallic Stents), By End User (Cardiac Centers, Hospitals) And Region For 2024-2031
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

冠状动脉支架市场评估 - 2024-2031

全球冠状动脉支架的需求正在稳步增长，这主要是由于心血管疾病盛行率的上升和支架技术的进步。心血管疾病仍然是全球死亡的主要原因，其影响因素包括久坐的生活方式、不健康的饮食、吸烟以及发达和发展中地区的人口老化。随着冠状动脉疾病盛行率的增加，对有效治疗方案的需求也在增加，从而推动了冠状动脉支架市场的发展。2023年市场规模将超过71.1亿美元，2031年将达到约138.7亿美元。

支架技术的创新，包括药物洗脱支架和生物可吸收血管支架，使这些设备更安全、更有效，进一步推动了它们在医学界的广泛采用。对具有成本效益和高效的冠状动脉支架的需求不断增长，使得市场从 2024 年到 2031 年的复合年增长率为 8.71%。

冠状动脉支架市场定义/概述

冠状动脉支架是由金属製成的小网管，用于治疗向心臟供血的冠状动脉狭窄或阻塞。它通常在经皮冠状动脉介入治疗 (PCI) 或血管成形术过程中植入。冠状动脉支架旨在支撑动脉壁，恢復血流并降低胸痛、心臟病和其他与冠状动脉疾病 (CAD) 相关的併发症的风险。冠状动脉支架有多种类型，包括裸金属支架、药物洗脱支架（DES）和生物可吸收支架，每种支架在安全性、有效性和寿命方面都有独特的优势。

由于支架技术的进步、微创手术需求的增加以及 CAD 盛行率的增加，冠状动脉支架显示出前景。生物可吸收支架和基于奈米技术的支架等新创新有望透过减少再狭窄和血栓形成等併发症来改善长期预后。此外，随着全球人口老化和医疗保健普及程度的提高，尤其是在新兴地区，对冠状动脉支架的需求将会增加，为市场创造新的成长机会。

心血管疾病（CVD）盛行率的上升会推动冠状动脉支架市场吗？

心血管疾病（CVD）盛行率的上升极大地推动了冠状动脉支架市场的发展，这主要是由于对有效治疗方案的需求不断增长来管理和缓解冠状动脉阻塞。根据世界卫生组织统计，心血管疾病每年导致全球 1,790 万人死亡，疾病预防控制中心报告称，冠心病影响着约 1,820 万美国成年人，冠状动脉支架的需求正在迅速增加。随着医疗保健系统旨在降低与心血管疾病相关的发病率和死亡率，越来越多的患者需要先进且易于使用的支架解决方案，从而推动市场成长。

老年人口的增加正在推动冠状动脉支架市场的发展。由于老化是冠状动脉疾病的主要危险因素，老年人数量的增加直接增加了冠状动脉支架的需求。据联合国称，到2050年，全球65岁及以上人口预计将达到15亿，其中发展中地区增长最快。在欧盟，近 20% 的经皮冠状动脉介入治疗 (PCI) 是在 75 岁或以上的患者中进行的，这表明衰老与支架置入术增加之间存在明显的关联。

高成本会影响冠状动脉支架市场的成长吗？

冠状动脉支架的高成本可能会影响冠状动脉支架市场的成长。支架治疗（尤其是先进的药物洗脱支架）的成本可能会让患者和医疗保健系统望而却步，尤其是在预算有限且医疗保险有限的低收入和中等收入国家。这些成本也会影响保险费，减少支架治疗的可及性，并减缓渗透率和市场成长，儘管人口老化和心血管疾病盛行率上升导致需求增加。

併发症的风险可能会影响冠状动脉支架市场的成长。支架血栓形成、再狭窄和出血等併发症会带来严重的健康风险，并可能导致额外的手术、医疗费用增加和患者犹豫。儘管支架技术的进步旨在最大限度地减少这些风险，但市场成长已经放缓，因为对这些潜在併发症的担忧可能会促使医疗保健提供者考虑替代治疗。

目录

第1章全球冠状动脉支架市场：简介

  • 市场概况
  • 调查范围
  • 先决条件

第 2 章执行摘要

第3章 验证市场研究研究方法

  • 数据挖掘
  • 确认
  • 一次资料
  • 数据源列表

第4章 全球冠状动脉支架市场展望

  • 概述
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
  • 波特的五力模型
  • 价值链分析

第5章全球冠状动脉支架市场：依类型

  • 概述
  • 裸金属支架 (BMS)
  • 药物洗脱支架（DES）

第6章全球冠状动脉支架市场：依材料类型

  • 概述
  • 聚合物支架
  • 金属支架

第7章全球冠状动脉支架市场：依最终用户分类

  • 概述
  • 心臟中心
  • 医院

第8章全球冠状动脉支架市场：按地区

  • 概述
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 亚太其他地区
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合酋长国
    • 南非
    • 其他中东和非洲

第9章全球冠状动脉支架市场：竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略
  • 公司产业足迹
  • 公司区域足迹
  • 王牌矩阵

第10章 公司简介

  • Abbott Laboratories
  • Boston Scientific
  • Medtronic
  • Terumo Corporation
  • B. Braun Melsungen
  • Cook Medical
  • Biosensors International
  • Biotronik, Johnson & Johnson
  • Meril Life Sciences

第11章 主要进展

  • 产品发布/开发
  • 併购
  • 业务拓展
  • 伙伴关係和联盟

第12章附录

  • 相关报导
简介目录
Product Code: 10608

Coronary Stent Market Valuation - 2024-2031

The global demand for coronary stents has been steadily increasing, driven primarily by the rising prevalence of cardiovascular diseases and advancements in stent technology. Cardiovascular disease remains a leading cause of death worldwide, with contributing factors such as sedentary lifestyles, unhealthy diets, smoking, and aging populations in developed and developing regions. As the incidence of coronary artery disease rises, so does the need for effective treatment options, propelling the market for coronary stents. The market size surpass USD 7.11 Billion valued in 2023 to reach a valuation of aroundUSD 13.87 Billion by 2031.

Innovations in stent technology, including drug-eluting stents and bioresorbable vascular scaffolds, have made these devices safer and more effective, further supporting their increased adoption in the medical community. The rising demand for cost-effective and efficient coronary stent is enabling the market grow at aCAGR of 8.71% from 2024 to 2031.

Coronary Stent Market: Definition/ Overview

A coronary stent is a small, metal mesh tube used to treat narrowed or blocked coronary arteries, which supply blood to the heart. It is typically implanted during a procedure known as percutaneous coronary intervention (PCI) or angioplasty. Coronary stents are designed to restore blood flow by supporting the artery walls, reducing the risk of chest pain, heart attacks, and other complications associated with coronary artery disease (CAD). There are several types of coronary stents, including bare-metal stents, drug-eluting stents (DES), and bioresorbable stents, each offering unique benefits in terms of safety, efficacy, and longevity.

Coronary stents is promising, driven by advancements in stent technology, growing demand for minimally invasive procedures, and the increasing prevalence of CAD. Emerging innovations, such as bioresorbable and nanotechnology-based stents, are expected to improve long-term outcomes by reducing complications like restenosis and thrombosis. Additionally, as the aging population grows and healthcare access improves globally, particularly in developing regions, the demand for coronary stents is likely to rise, creating new growth opportunities in the market.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will the Rising Prevalence of Cardiovascular Diseases (CVD) Drive the Coronary Stent Market?

The rising prevalence of cardiovascular diseases (CVD) is significantly driving the coronary stent market, primarily due to the growing need for effective treatment options to manage and alleviate coronary artery blockages. With cardiovascular diseases causing 17.9 million deaths globally each year, according to the WHO, and coronary heart disease affecting around 18.2 million U.S. adults, as reported by the CDC, the demand for coronary stenting procedures has surged. This increasing patient pool necessitates advanced and accessible stent solutions, driving market growth as healthcare systems aim to reduce CVD-related morbidity and mortality.

The growing elderly population is indeed fueling the coronary stent market. As age is a primary risk factor for coronary artery disease, the rising number of elderly individuals directly increases the demand for coronary stents. According to the United Nations, the global population aged 65 and above is expected to reach 1.5 billion by 2050, with developing regions seeing the fastest growth. In the EU, nearly 20% of all percutaneous coronary interventions (PCIs) target patients aged 75 or older, illustrating a clear link between aging populations and increased stent procedures.

Will the High-Cost impact the Growth of the Coronary Stent Market?

The high cost of coronary stents can impact the growth of the coronary stent market. The expense of stent procedures, particularly for advanced drug-eluting stents, can be prohibitive for patients and healthcare systems, especially in low- and middle-income countries where budget constraints and limited healthcare coverage are prevalent. These costs also impact insurance premiums, making stent procedures less accessible, which can slow the adoption rate and market growth despite the increasing demand driven by aging populations and rising cardiovascular disease prevalence.

The risk of complications can impact the growth of the coronary stent market. Complications such as stent thrombosis, restenosis, and bleeding pose significant health risks, which can lead to additional procedures, increased medical costs, and patient hesitancy. Concerns over these potential complications may prompt healthcare providers to consider alternative treatments, thus limiting the market's growth despite advancements in stent technology aimed at minimizing these risks.

Category-Wise Acumens

Will the Reduced Restenosis Raise the Drug-Eluting Stents (DES) Segment for the Coronary Stent Market?

Drug-Eluting Stents (DES) Segment is dominating the coronary stent market. Reduced restenosis rates are likely to propel the growth of the Drug-Eluting Stents (DES) segment in the coronary stent market. DES is designed to release medication that inhibits cell proliferation, significantly reducing the risk of restenosis compared to bare-metal stents. This improved efficacy in preventing artery re-narrowing makes DES a preferred choice for patients and healthcare providers, driving higher adoption rates and supporting market growth in this segment.

Technological advancements are propelling the drug-eluting stents (DES) segment within the coronary stent market. Innovations such as improved biocompatible polymers, biodegradable stents, and advanced drug coatings have enhanced the safety and effectiveness of DES, reducing complications like restenosis and improving patient outcomes. These advancements make DES an increasingly preferred choice among healthcare providers, driving growth within this segment as they seek safer and more effective solutions for coronary artery disease.

Will the Proven Efficacy Fuel the Metallic Stents Segment for the Coronary Stent Market?

The metallic stents segment is ruling the coronary stent market. The proven efficacy of metallic stents is promoting growth in this segment of the coronary stent market. Metallic stents, particularly drug-eluting and bare-metal stents, have shown reliable results in maintaining vessel patency and reducing the risk of acute complications. Their durability and established clinical success make them a trusted choice for many cardiologists, especially in complex cases, driving continued demand and growth within this segment as they offer consistent and effective treatment for coronary artery disease.

Cost-effectiveness is promoting the metallic stents segment within the coronary stent market. Metallic stents, especially bare-metal stents, offer a more affordable option compared to drug-eluting or biodegradable stents, making them attractive for patients and healthcare systems in cost-sensitive regions. Their durability and relatively lower cost make metallic stents a practical choice for managing coronary artery disease, thus driving demand in regions with budget constraints or limited healthcare funding.

Country/Region-wise Acumens

Will the Rising Prevalence of Cardiovascular Diseases (CVD) Accelerate the North American Region for Coronary Stent Market?

North America's dominance in the coronary stent market. The rising prevalence of cardiovascular diseases (CVD) is likely to accelerate the coronary stent market' in North America. With about 20.1 million adults aged 20 and older currently affected by coronary artery disease (CAD) and an expected increase to 28.5 million by 2040, there is a growing demand for coronary stents. This demand stems from the need for effective treatment options, as coronary stents play a critical role in managing CAD by improving blood flow and reducing the risk of severe cardiac events, thereby driving market growth.

The advanced healthcare infrastructure in North America is accelerating the growth of the coronary stent market. The region's extensive network of around 6,090 hospitals in the U.S. alone enables widespread access to cardiac procedures, with over 1 million coronary stent procedures performed annually. This accessibility, combined with skilled healthcare professionals and advanced medical technologies, ensures timely treatment for cardiovascular diseases, thereby driving demand and growth in the coronary stent market.

Will the Large Patient Pool Expand the Asia Pacific Region for the Coronary Stent Market?

Asia Pacific is rapidly growing in the coronary stent market due to several factors. The large patient pool in the Asia Pacific region is significantly escalating the growth of the coronary stent market. The region accounts for nearly 60% of the global cardiovascular disease burden, as reported by the Asian Pacific Society of Cardiology. Additionally, Japan's aging population, with 27.6% affected by cardiovascular diseases, highlights the demand for coronary interventions. This high prevalence, combined with the growing need for accessible treatment options, drives the expansion of the coronary stent market in Asia Pacific.

The growing disease burden is significantly escalating the coronary stent market in the Asia Pacific region. With China reporting over 330 million patients with cardiovascular diseases and India expecting its coronary artery disease cases to rise from 65.1 million to 75 million by 2030, the demand for coronary stents is increasing. This high prevalence of cardiovascular conditions is driving the need for coronary stent procedures, as healthcare providers seek effective treatments to manage the rising cases and improve patient outcomes across the region.

Competitive Landscape

The coronary stent market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the coronary stent market include:

  • Abbott Laboratories, Boston Scientific, Medtronic, Terumo Corporation, Braun Melsungen, Cook Medical, Biosensors International, Biotronik, Johnson & Johnson, Meril Life Sciences

Latest Developments

  • In April 2021, Abbott announced the launched of coronary imaging platform Ultreon 1.0 Software powered by AI in Europe. The software has been launched with an aim to improve detection of calcium-based blockages and measure vessel diameter during coronary stenting procedures.
  • In February 2021, Cardiovascular Systems Inc established a partnership with Chansu Vascular Technologies, LLC to produce peripheral and coronary drug-coated balloons for use in drug-eluting stents.

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL CORONARY STENT MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL CORONARY STENT MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL CORONARY STENT MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 Bare-Metal Stents (BMS)
  • 5.3 Drug-Eluting Stents (DES)

6 GLOBAL CORONARY STENT MARKET, BY MATERIAL TYPE

  • 6.1 Overview
  • 6.2 Polymer-Based Stents
  • 6.3 Metallic Stents

7 GLOBAL CORONARY STENT MARKET, BY END USER

  • 7.1 Overview
  • 7.2 Cardiac Centers
  • 7.3 Hospitals

8 GLOBAL CORONARY STENT MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Argentina
    • 8.5.3 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 South Africa
    • 8.6.4 Rest of Middle East and Africa

9 GLOBAL CORONARY STENT MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies
  • 9.4 Company Industry Footprint
  • 9.5 Company Regional Footprint
  • 9.6 Ace Matrix

10 COMPANY PROFILES

  • 10.1 Abbott Laboratories
    • 10.1.1 Overview
    • 10.1.2 Company Insights
    • 10.1.3 Business Breakdown
    • 10.1.4 Product Outlook
    • 10.1.5 Key Developments
    • 10.1.6 Winning Imperatives
    • 10.1.7 Current Focus and Strategies
    • 10.1.8 Threat From Competition
    • 10.1.9 Swot Analysis
  • 10.2 Boston Scientific
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Medtronic
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Terumo Corporation
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 B. Braun Melsungen
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Cook Medical
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Biosensors International
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Biotronik, Johnson & Johnson
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Meril Life Sciences
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 Appendix

  • 12.1 Related Reports